| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Michael Carulli is Chief Financial Officer at PMVP. Michael Carulli's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $83K at current prices.
The PMVP filings lean toward selling, a net 31,140 shares.
Michael Carulli has 6 Form 4 filings on record from January 2024 to March 2026, all as Chief Financial Officer at PMV Pharmaceuticals (PMVP), 2024–2026.
The 11 reported transactions were 5 option or other derivative awards, 3 dispositions back to the company, 2 open-market sales and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $34K.
The largest open-market sale was 28,249 shares of PMVP at an average $1.06 on July 1, 2025, about $30K. Twelve months later PMVP was up 18%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.